Nanjing Pharmaceutical Co (SHSE:600713) 5-Year EBITDA Growth Rate : 16.80% (As of Mar. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Nanjing Pharmaceutical Co 5-Year EBITDA Growth Rate?

Nanjing Pharmaceutical Co's EBITDA per Share for the three months ended in Mar. 2024 was ¥0.27.

During the past 12 months, Nanjing Pharmaceutical Co's average EBITDA Per Share Growth Rate was 6.60% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 14.70% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 16.80% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 8.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Nanjing Pharmaceutical Co was 33.10% per year. The lowest was -16.70% per year. And the median was 14.50% per year.

Competitive Comparison of Nanjing Pharmaceutical Co's 5-Year EBITDA Growth Rate

For the Drug Manufacturers - General subindustry, Nanjing Pharmaceutical Co's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nanjing Pharmaceutical Co's 5-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nanjing Pharmaceutical Co's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Nanjing Pharmaceutical Co's 5-Year EBITDA Growth Rate falls into.

Nanjing Pharmaceutical Co 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Nanjing Pharmaceutical Co (SHSE:600713) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Nanjing Pharmaceutical Co 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Nanjing Pharmaceutical Co's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Nanjing Pharmaceutical Co (SHSE:600713) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nanjing Pharmaceutical Co Ltd (SHSE:600713) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 486 Zhongshan East Road, Nanjing, Jiangsu, CHN, 210002

Website

http://www.guangyuyuan.com

Nanjing Pharmaceutical Co Ltd is engaged in the pharmaceutical service business.

Executives

Xiao Hong	senior management
Peng Yu Ping	senior management
She Ping	Supervisors
Jiang Xiao Jun	senior management
Teng Xue Wu	senior management
Zhou Jian Jun	senior management
Li Yi	Director
Huang Yan Li	Supervisors
Tang Jian Zhong	senior management
Zhang Yan Hui	senior management
Zhou Yao Ping	Director
Wang Hui Qing	senior management
He Jin Geng	senior management
Ding Feng Jun	Director
Liang Yu Tang	Director

Nanjing Pharmaceutical Co (SHSE:600713) Headlines

No Headlines